These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32656742)

  • 1. Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism.
    Takahashi R; Sato Y; Kimishima M; Shiohara T; Ohyama M
    Int J Clin Oncol; 2020 Oct; 25(10):1861-1869. PubMed ID: 32656742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
    Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
    J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
    Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
    Front Immunol; 2020; 11():579894. PubMed ID: 33072126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma.
    Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H
    Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
    Bochem J; Zelba H; Amaral T; Spreuer J; Soffel D; Eigentler T; Wagner NB; Uslu U; Terheyden P; Meier F; Garbe C; Pawelec G; Weide B; Wistuba-Hamprecht K
    PLoS One; 2019; 14(8):e0221301. PubMed ID: 31419253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
    Koppolu V; Rekha Vasigala VK
    J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
    Ding G; Shen T; Yan C; Zhang M; Wu Z; Cao L
    BMC Cancer; 2019 Nov; 19(1):1053. PubMed ID: 31694582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.
    Hatae R; Chamoto K; Kim YH; Sonomura K; Taneishi K; Kawaguchi S; Yoshida H; Ozasa H; Sakamori Y; Akrami M; Fagarasan S; Masuda I; Okuno Y; Matsuda F; Hirai T; Honjo T
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31855576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma.
    Yoshida T; Ichikawa J; Giuroiu I; Laino AS; Hao Y; Krogsgaard M; Vassallo M; Woods DM; Stephen Hodi F; Weber J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
    Carreau NA; Pavlick AC
    Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.